15.80
Arrowhead Pharmaceuticals Inc stock is traded at $15.80, with a volume of 1.20M.
It is up +0.60% in the last 24 hours and up +0.00% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$15.71
Open:
$15.9278
24h Volume:
1.20M
Relative Volume:
0.68
Market Cap:
$2.18B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-11.37
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-2.83%
1M Performance:
+0.00%
6M Performance:
-20.52%
1Y Performance:
-44.68%
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ARWR
Arrowhead Pharmaceuticals Inc
|
15.80 | 2.17B | 181.74M | -143.97M | 9.60M | -1.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-05-24 | Initiated | Goldman | Neutral |
Dec-04-23 | Initiated | BofA Securities | Buy |
Sep-19-23 | Initiated | Citigroup | Neutral |
Jul-21-23 | Initiated | TD Cowen | Outperform |
May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Apr-26-23 | Initiated | SMBC Nikko | Outperform |
Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-19-22 | Resumed | Goldman | Buy |
Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-16-20 | Initiated | UBS | Buy |
Nov-19-20 | Initiated | Citigroup | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Mar-17-20 | Initiated | Goldman | Neutral |
Jan-21-20 | Initiated | SVB Leerink | Underperform |
Dec-13-19 | Initiated | Oppenheimer | Perform |
Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
Nov-27-19 | Reiterated | B. Riley FBR | Buy |
Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
Oct-03-19 | Initiated | Robert W. Baird | Outperform |
Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
11 Best Future Stocks to Buy Now - Insider Monkey
Why Arrowhead Pharmaceuticals Inc. stock attracts strong analyst attentionConfirmed Setup With Expert Accuracy Supported - metal.it
Competitive Positioning of Arrowhead Pharmaceuticals Inc.: Is It Leading or LaggingStock Market Entry Timing Signals Revealed - metal.it
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals Inc. Inches Above Key Support — Safe to HoldTarget Return Focused Trade Insights Shared - metal.it
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? - Benzinga
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - BioSpace
Sarepta Owes $100 Million to Partner as Financial Pressure Grows - Bloomberg
Arrowhead, Sarepta Advance on Pact - Baystreet.ca
Arrowhead (ARWR) Secures $100 Million Milestone from Sarepta - GuruFocus
Arrowhead (ARWR) Secures $100M Milestone from Sarepta in Clinica - GuruFocus
Is it the right time to buy Arrowhead Pharmaceuticals Inc. stockInvest with confidence backed by data - jammulinksnews.com
How volatile is Arrowhead Pharmaceuticals Inc. stock compared to the marketRapid wealth multiplication - jammulinksnews.com
Is Arrowhead Pharmaceuticals Inc. stock overvalued or undervaluedMarket-leading capital gains - jammulinksnews.com
Arrowhead Shares Bumpy After Partner Troubles - Los Angeles Business Journal
How strong is Arrowhead Pharmaceuticals Inc. company’s balance sheetHigh-return market picks - jammulinksnews.com
Arrowhead Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveTop Analyst Picks - metal.it
Is Arrowhead Pharmaceuticals Inc. a growth stock or a value stockUnlock daily market insights for better decisions - jammulinksnews.com
How Arrowhead Pharmaceuticals Inc. stock performs during market volatilityMinimized Risk Maximum Return - metal.it
What are Arrowhead Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving market trends - jammulinksnews.com
What are the latest earnings results for Arrowhead Pharmaceuticals Inc.High-margin investment plays - jammulinksnews.com
Why is Arrowhead Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - jammulinksnews.com
When is Arrowhead Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid capital gains with smart investing - jammulinksnews.com
What are analysts’ price targets for Arrowhead Pharmaceuticals Inc. in the next 12 monthsUnlock the power of real-time market data - jammulinksnews.com
Is Arrowhead Pharmaceuticals Inc. a good long term investmentFree Consultation - PrintWeekIndia
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)July 24, 2025 - BioSpace
What analysts say about Arrowhead Pharmaceuticals Inc. stockExplosive returns - Autocar Professional
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement - MSN
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns - MSN
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - BioSpace
Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks - Reuters
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement By Stocktwits - Investing.com India
Arrowhead Pharmaceuticals (ARWR) Awaits Sarepta Payments Amid Re - GuruFocus
Arrowhead Stays Confident In Sarepta’s Commitment Despite Restructuring - Finimize
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Sarepta’s licensing partner Arrowhead expects near-term payments despite setbacks - whbl.com
Arrowhead expects Sarepta to meet deal terms (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPhenomenal capital gains - jammulinksnews.com
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):